查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1471077

神經調節市場：按技術、按應用分類 - 2024-2030 年全球預測

Neuromodulation Market by Technology (Deep Brain Stimulation, Gastric Stimulation, Sacral Nerve Stimulation), Application (Chronic Pain, Dystonia, Essential Tremor) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年神經調節市場規模為77.6億美元，預計2024年將達86.1億美元，2030年將達到166.2億美元，複合年成長率為11.50%。

神經調節設備和治療方法旨在將電、化學或藥劑輸送到神經系統以調節其活動。該技術主要用於治療多種疾病，包括慢性疼痛、癲癇、帕金森氏症和尿失禁。慢性疼痛和神經系統疾病的增加迫切需要神經調節治療。此外，人們對神經調節技術益處的認知不斷提高、醫療保健支出增加以及政府為促進神經系統治療的努力而做出的努力，都有助於神經調節技術的廣泛採用。然而，神經調節設備和系統的產品召回以及潛在的安全和健康風險阻礙了該技術的普及。此外，治療的侵入性，加上有關醫療設備核准的嚴格規定，可能會減緩神經調節策略的採用。然而，主要企業正在研究非侵入性方法，以擴大患者覆蓋範圍並保持患者依從性。開發個人化神經調節療法有可能滿足個別患者的需求和生理學並提供更好的治療結果。生物相容性材料的進步、引入無線技術來控制神經調節設備以及利用巨量資料分析來解釋神經調節結果可能會為該技術的發展提供新的機會。

主要市場統計
基準年[2023] 77.6億美元
預測年份 [2024] 86.1億美元
預測年份 [2030] 166.2億美元
複合年成長率（%） 11.50%

技術 對運動障礙和精神疾病的深部腦部刺激療法的需求不斷成長

深部腦部刺激 (DBS) 是治療方法帕金森氏症、自發性震顫和肌張力不全症失調等運動障礙的方法。電極被植入大腦的特定區域，產生控制異常脈衝的電脈衝。 DBS 的需要通常是根據嚴重程度和對其他治療的反應來決定。胃刺激療法，也稱為胃電刺激（GES），針對胃的肌肉和神經，通常用於治療肥胖和胃輕癱。當患者對傳統治療方法沒有反應並需要替代干預措施來控制症狀和體重時，就會出現這種需求。薦椎神經刺激主要用於治療尿失禁和大便失禁。對保守治療沒有充分反應的失禁患者是 SNS 的候選者，SNS 使用可植入裝置來電刺激薦骨神經。脊髓刺激是一種治療慢性疼痛的策略，包括腰部手術失敗症候群、複雜性局部疼痛症候群和慢性頑固性疼痛。當其他疼痛管理治療無法提供足夠的緩解時，可選擇 SCS。它使用低壓電刺激脊髓，在疼痛訊號到達大腦之前阻止它們。迷走神經刺激主要用於治療癲癇和憂鬱症。 VNS適用於不適合手術或對藥物治療有抵抗力的患者。這種治療方法會向迷走神經發送電脈衝以調節神經傳遞。

應用範例 帕金森氏症在全球範圍內呈上升趨勢

慢性疼痛治療​​是神經調節的主要應用領域之一。脊髓刺激設備(SCS) 等設備可以透過向脊髓發送電脈衝來顯著減輕疼痛。藥物治療的限制和避免長期使用鴉片類藥物的願望產生了基於需求的偏好。肌張力不全症的神經調節通常涉及深部腦部刺激（DBS）以減少不自主的肌肉收縮。患者的偏好取決於手術的安全性以及藥物治療不足時症狀改善的潛力。特發性震顫通常以針對丘腦的 DBS 系統來治療，以抑制震顫症狀。對藥物治療無反應的患者對此類系統的需求正在增加。胃輕癱的特徵是排放延遲，可以透過胃電刺激來治療。對於對傳統治療沒有反應的患者，強迫性精神官能症(OCD) 可以透過 DBS 進行治療，DBS 的目標是與疾病相關的大腦區域。 DBS主要用於透過神經調節來治療帕金森氏症，可以緩解僵硬、心搏過緩緩和震顫等症狀。當即使經過藥物治療運動症狀也沒有改善時選擇它。頑固性癲癇的神經調節包括迷走神經刺激（VNS）和反應性神經刺激（RNS）。這些治療方法適用於不適合手術或患有難治性癲癇的患者。迷走神經刺激可有效抗治療性憂鬱症(TRD)，並有助於調節情緒和情緒調節途徑。當多種抗憂鬱症不能提供足夠的臨床療效時選擇它。骶神經調節可有效治療尿失禁和大便失禁，並且由於有效的藥物選擇有限而獲得認可。

區域洞察

架構區域以美國和加拿大為中心，其特點是強大的醫療保健架構以及有利的報銷和保險政策，這些政策正在影響神經調節技術的採用。此外，該地區對神經和心理健康問題的認知很高，這也推動了該技術在患者中的認可。患者情況反映了對 FDA 批准的創新治療方法的偏好以及採用新技術的意願。隨著公司和研究機構尋求擴大神經調節治療的功效和範圍，美洲地區正在神經調節領域進行持續的研究和大量投資，並擁有強大的專利格局。在歐盟（EU），預期壽命的延長和有利的報銷政策是推動神經調節市場需求的關鍵因素。患者的需求集中在人口老化中普遍存在的慢性病的管理上，而客戶的購買行為則受到公共醫療系統提供的醫療保險的影響。重點是在整個歐盟範圍內制定通用標準和法規，以放寬市場准入並確保病患安全。歐盟的特點是嚴格的醫療保健法規，這正在推動創新以提高神經調節技術的安全性和準確性。隨著印度和中國等國家神經系統疾病的增加，以及日本人口的快速老化，對神經調節治療的需求日益成長。政府為意識提升和改善醫療基礎設施所做的努力正在推動亞太地區神經調節的成長。

FPNV定位矩陣

FPNV定位矩陣對於評估神經調節市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對神經調節市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. 神經調節市場的市場規模與預測是多少？

2.在神經調節市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3. 神經調控市場的技術趨勢和法規結構是什麼？

4.神經調節市場主要廠商的市場佔有率是多少？

5. 進入神經調節市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口老化和神經系統疾病在世界各地變得越來越普遍。
      • 神經刺激系統和解決方案的研究舉措和臨床試驗
      • 政府努力擴大神經系統疾病和失調的治療方法機會
    • 抑制因素
      • 神經調節和神經刺激設備或系統的產品回收數量
    • 機會
      • 最佳化神經調節策略效率與安全性的創新
      • 世界各地正在核准神經調節設備和治療方法
    • 任務
      • 該技術的侵入性和技術限制
  • 市場區隔分析
    • 技術：針對運動障礙和精神疾病的深部腦部刺激療法的需求正在成長
    • 應用：全球帕金森氏症發生率增加
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章神經調節市場：依技術分類

  • 腦深部電刺激療法
  • 胃刺激
  • 薦椎神經刺激
  • 脊髓刺激
  • 迷走神經刺激

第7章神經調節市場：依應用分類

  • 慢性疼痛
  • 肌張力不全症
  • 自發性震顫
  • 胃輕癱
  • 強迫性精神官能症
  • 帕金森氏症
  • 難治性癲癇
  • 抗治療性憂鬱症
  • 尿失禁

第8章美洲神經調節市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區神經調節市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的神經調節市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • GrayMatters Health 在美國推出經 FDA核准的新的自動神經調節 PTSD治療方法
    • Dr Reddy's 在印度推出用於偏頭痛管理的穿戴式設備
    • Galderma 在 Liquid實況活動中展示了大膽的神經調節雄心
  • 戰略分析和建議

第12章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-036C5CF3B4DB

[180 Pages Report] The Neuromodulation Market size was estimated at USD 7.76 billion in 2023 and expected to reach USD 8.61 billion in 2024, at a CAGR 11.50% to reach USD 16.62 billion by 2030.

Neuromodulation devices and therapies are designed to deliver targeted electrical, chemical, or pharmaceutical agents to the nervous system in order to modulate its activity. This technology is primarily used for the treatment of various disorders, such as chronic pain, epilepsy, Parkinson's disease, and urinary incontinence, among others. Growing incidences of chronic pain and neurological disorders have created an urgent need for neuromodulation treatments. Furthermore, increased awareness about the benefits of neuromodulation techniques, rising healthcare expenditure, and government initiatives to promote access to neurological therapies are contributing to the growing adoption of neuromodulation. However, incidences of product recall of neuromodulation devices and systems and the possibility of safety and health risks hamper the widespread growth of the technology. Additionally, the invasiveness of the therapy, coupled with strict regulations regarding the approval of medical devices, can delay the adoption of neuromodulation strategies. However, key players are researching non-invasive methods to expand the patient reach and maintain patient compliance. Developing personalized neuromodulation therapies could provide superior outcomes by catering to individual patient needs and physiology. Advances in biocompatible materials, incorporating wireless technologies to control neuromodulation devices, and utilizing big data analytics to interpret neuromodulation outcomes can provide new opportunities for the growth of the technology.

KEY MARKET STATISTICS
Base Year [2023] USD 7.76 billion
Estimated Year [2024] USD 8.61 billion
Forecast Year [2030] USD 16.62 billion
CAGR (%) 11.50%

Technology: Increasing need for deep brain stimulation therapies for movement disorders and psychiatric issues

Deep brain stimulation (DBS) is a treatment for targeting movement disorders such as Parkinson's disease, essential tremor, and dystonia. It involves the implantation of electrodes within certain areas of the brain, producing electrical impulses that regulate abnormal impulses. The need for DBS is generally based on the severity and responsiveness of the condition to other treatments. Gastric stimulation, also known as gastric electrical stimulation (GES), targets the stomach's muscles and nerves and is typically used for treating obesity and gastroparesis. The need arises when patients are unresponsive to traditional treatments and require alternative interventions to manage symptoms or weight. Sacral nerve stimulation is mainly used to treat urinary and fecal incontinence. Patients with incontinence who do not respond adequately to conservative therapies may be candidates for SNS, which involves the electrical stimulation of the sacral nerve through an implantable device. Spinal cord stimulation is a treatment strategy for chronic pain situations, including failed back surgery syndrome, complex regional pain syndrome, and chronic intractable pain. SCS is chosen when other pain management therapies fail to provide sufficient relief. It involves the delivery of low-voltage electrical stimulation to the spinal cord, which then blocks pain signals before they reach the brain. Vagus nerve stimulation is primarily used for the treatment of epilepsy and depression. VNS is considered for patients who are not suitable for surgery and whose conditions are refractory to medication. The therapy delivers electrical impulses to the vagus nerve to modulate neurotransmission.

Application: Rising incidences of Parkinson's disease across the world

Chronic pain treatment is one of the primary applications of neuromodulation. Devices such as spinal cord stimulators (SCS) can provide significant pain relief by sending electrical impulses to the spinal cord. Need-based preference emerges from the limitations of pharmacological treatments and the desire to avoid long-term opioid use. Neuromodulation for dystonia often involves deep brain stimulation (DBS) to reduce involuntary muscle contractions. Patient preference relies on procedural safety and the possibility of symptom improvement when medications are not adequate. Essential tremor is commonly addressed with DBS systems targeting the thalamus to suppress tremor symptoms. The need for these systems rises among patients who are unresponsive to medications. Gastroparesis, characterized by delayed stomach emptying, can be treated with gastric electrical stimulation. Obsessive-compulsive disorder (OCD) can be managed with DBS, targeting brain regions linked to the disorder for patients who don't respond to conventional treatment. Parkinson's disease treatment through neuromodulation mainly involves DBS, which can alleviate symptoms such as rigidity, bradykinesia, and tremor. This option becomes a preference when patients experience motor symptoms despite medication. Neuromodulation for refractory epilepsy includes vagus nerve stimulation (VNS) and responsive neurostimulation (RNS). These therapies are indicated for patients not suitable for surgery or those with intractable epilepsy. Treatment-resistant depression (TRD) can benefit from vagus nerve stimulation, which helps in modulating mood and emotional regulation pathways. Preference arises when multiple antidepressants fail to provide adequate clinical benefits. Sacral neuromodulation is effective for managing urinary and fecal incontinence, with acceptance increasing due to limited effective pharmaceutical options.

Regional Insights

The Americas region, particularly the U.S. and Canada, is characterized by the presence of a robust healthcare architecture and favorable reimbursement and insurance policies, which has shaped the adoption of neuromodulation technologies. Additionally, the awareness regarding neurological disorders and mental health issues is high in this region, thereby driving the recognition of the technology among patients. The patient landscape reflects a preference for innovative, FDA-approved treatments and a willingness to adopt new technologies. The Americas region exhibits a robust patent landscape with ongoing research and substantial investments in the neuromodulation space, as companies and research institutions aim to advance the efficacy and scope of neuromodulation therapies. In the European Union, increased life expectancy and favorable reimbursement policies are significant factors driving the need for the neuromodulation market. Patient needs are centered around the management of chronic conditions prevalent in an aging population, and customer purchasing behavior is influenced by the healthcare coverage provided by public health systems. There is a focus on creating common standards and regulations across the EU to facilitate market access and ensure patient safety. The EU is characterized by stringent healthcare regulations, which have fuelled several innovations to improve the safety and precision of neuromodulation technologies. The increasing incidences of neurological diseases in countries such as India and China and a rapidly aging population in Japan have augmented the need for neuromodulation therapies. Health awareness and government initiatives to advance the healthcare infrastructure can create a robust ground for the growth of neuromodulation in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neuromodulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neuromodulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neuromodulation Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BioControl by Merck, BioElectronics Corporation, Boston Scientific Corporation, Dr Reddys Laboratories Limited, EndoStim, Inc., Galderma S.A., GrayMatters Health, Impulse Dynamics, Livanova, Mainstay Medical, Medtronic PLC, MicroTransponde, NeuroMetrix, Neuronetics, Inc., NeuroPace, Inc., NeuroSigma, Inc., Nevro Corp., Saluda Medical, SceneRay Corporation, Limited, Soterix Medical, and Synapse Biomedical.

Market Segmentation & Coverage

This research report categorizes the Neuromodulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Deep Brain Stimulation
    • Gastric Stimulation
    • Sacral Nerve Stimulation
    • Spinal Cord Stimulation
    • Vagus Nerve Stimulation
  • Application
    • Chronic Pain
    • Dystonia
    • Essential Tremor
    • Gastroparesis
    • Obsessive Compulsive Disorder
    • Parkinson's Disease
    • Refractory Epilepsy
    • Treatment Resistant Depression
    • Urinary Fecal Incontinence
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Neuromodulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neuromodulation Market?

3. What are the technology trends and regulatory frameworks in the Neuromodulation Market?

4. What is the market share of the leading vendors in the Neuromodulation Market?

5. Which modes and strategic moves are suitable for entering the Neuromodulation Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the aging population across the world and prevalence of neurological disorders
      • 5.1.1.2. Research initiatives and clinical trials for neurostimulation systems and neuromodulation solutions
      • 5.1.1.3. Government initiatives to expand access to therapies for neurological diseases and disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product recall of neuromodulation and neurostimulation devices or systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations to optimize the efficiency and safety of neuromodulation strategies
      • 5.1.3.2. Ongoing approvals for neuromodulation devices and treatments across the world
    • 5.1.4. Challenges
      • 5.1.4.1. Invasiveness and technical limitations of the technology
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Increasing need for deep brain stimulation therapies for movement disorders and psychiatric issues
    • 5.2.2. Application: Rising incidences of Parkinson's disease across the world
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Neuromodulation Market, by Technology

  • 6.1. Introduction
  • 6.2. Deep Brain Stimulation
  • 6.3. Gastric Stimulation
  • 6.4. Sacral Nerve Stimulation
  • 6.5. Spinal Cord Stimulation
  • 6.6. Vagus Nerve Stimulation

7. Neuromodulation Market, by Application

  • 7.1. Introduction
  • 7.2. Chronic Pain
  • 7.3. Dystonia
  • 7.4. Essential Tremor
  • 7.5. Gastroparesis
  • 7.6. Obsessive Compulsive Disorder
  • 7.7. Parkinson's Disease
  • 7.8. Refractory Epilepsy
  • 7.9. Treatment Resistant Depression
  • 7.10. Urinary Fecal Incontinence

8. Americas Neuromodulation Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Neuromodulation Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Neuromodulation Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. GrayMatters Health Launches New FDA-Cleared Self-Neuromodulation PTSD Therapy in the United States
    • 11.3.2. Dr. Reddy's Unveils Wearable for Migraine Management in India
    • 11.3.3. Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. NEUROMODULATION MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROMODULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NEUROMODULATION MARKET DYNAMICS
  • FIGURE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROMODULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL NEUROMODULATION MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 74. AUSTRALIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. AUSTRALIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 78. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 79. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. INDIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 82. INDIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 83. INDIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. INDIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. INDONESIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 86. INDONESIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 87. INDONESIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. INDONESIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. JAPAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 90. JAPAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 91. JAPAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. JAPAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. MALAYSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 94. MALAYSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 95. MALAYSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MALAYSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. PHILIPPINES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. PHILIPPINES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. SINGAPORE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 102. SINGAPORE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 103. SINGAPORE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. SINGAPORE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. TAIWAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 110. TAIWAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 111. TAIWAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. TAIWAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. THAILAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 114. THAILAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 115. THAILAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. THAILAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. VIETNAM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 118. VIETNAM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 119. VIETNAM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. VIETNAM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 127. DENMARK NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. DENMARK NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. DENMARK NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. DENMARK NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. EGYPT NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 132. EGYPT NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 133. EGYPT NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. EGYPT NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. FINLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 136. FINLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 137. FINLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. FINLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. FRANCE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. FRANCE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. FRANCE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. FRANCE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. GERMANY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 144. GERMANY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 145. GERMANY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. GERMANY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. ISRAEL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 148. ISRAEL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 149. ISRAEL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. ISRAEL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. ITALY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 152. ITALY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 153. ITALY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. ITALY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. NETHERLANDS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. NETHERLANDS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. NETHERLANDS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. NETHERLANDS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. NIGERIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 160. NIGERIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 161. NIGERIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. NIGERIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. NORWAY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 164. NORWAY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 165. NORWAY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. NORWAY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. POLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 168. POLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 169. POLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. POLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. QATAR NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. QATAR NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. QATAR NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. QATAR NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. RUSSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 176. RUSSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 177. RUSSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. RUSSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. SPAIN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 188. SPAIN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 189. SPAIN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. SPAIN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. SWEDEN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. SWEDEN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. SWEDEN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. SWEDEN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. SWITZERLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 196. SWITZERLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 197. SWITZERLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. SWITZERLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. TURKEY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 200. TURKEY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 201. TURKEY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. TURKEY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 208. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 209. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 212. NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2023